The Phase IIb POWER 1 and 2 trials compared the efficacy and safety of darunavir plus low-dose ritonavir (darunavir/ritonavir) with currently available PIs in highly treatment-experienced patients ...

Extended-course nirmatrelvir/ritonavir yields a meaningful reduction in symptoms for some patients with long COVID, but not all benefits persist, according to a case series published online Jan.